VGXI Wins Best Contract Manufacturing Organization for the 2020 Vaccine Industry Excellence Awards

Share Article

Texas-based plasmid DNA CDMO VGXI, Inc. was recognized as the winner of the 2020 ViE Award for Best Contract Manufacturing Organization at the World Vaccine Congress Washington.

VGXI Vaccine Industry Excellence Awards
This award is a testament to the dedication of the entire VGXI team to delivering exceptional quality products and services, with the goal of ensuring both patient safety and clinical success for these next generation vaccines and therapies.

VGXI, Inc., a contract development and manufacturing organization specialized in production of pre-clinical through cGMP grade DNA-based biopharmaceuticals, announced it has been recognized as the winner for Best Contract Manufacturing Organization on September 30, 2020 at the Vaccine Industry Excellence (ViE) Awards. The ViE Awards are part of the annual World Vaccine Congress in Washington D.C., which was held virtually in 2020 due to the coronavirus pandemic. The awards are designed to highlight the efforts, positive contributions, and accomplishments of companies and individuals across the vaccine industry.

Finalists for the 12 highly competitive categories are determined though a rigorous process of industry nominations and shortlist voting over several months. The ViE Scientific Advisory Board oversees final judging and selection of winners.

“VGXI is honored to accept the award for Best CMO, and we want to reach out to all of our clients, partners, and collaborators in appreciation of their support,” stated VGXI COO Dorothy Peterson. “The award is a testament to the dedication of the entire VGXI team to delivering exceptional quality products and services, with the goal of ensuring both patient safety and clinical success for these next generation vaccines and therapies.”

Best CMO recognition comes as VGXI is in the process of establishing a new, expanded manufacturing facility to meet accelerating worldwide demand from the DNA vaccine, immunotherapy, and gene therapy industries. The new facility is targeted to be operational in early 2022 and will dramatically increase VGXI’s manufacturing capacity and flexibility for production of DNA and RNA products.

VGXI, Inc. is a leading provider of manufacturing and development services for DNA vaccines and gene therapies. The company has a reputation of success in manufacturing DNA products under cGMP conditions for clinical trials in the US, EU, Asia, Canada, and Australia, and its cGMP and non-GMP products have passed rigorous reviews by several international regulatory agencies. VGXI’s ability to work with unique requirements and create custom manufacturing solutions is based on its patented manufacturing process, flexible cGMP production facility, and experienced development team. VGXI, Inc. is a wholly-owned subsidiary CDMO of GeneOne Life Science, Inc. To learn more or request a quote, visit

GeneOne Life Science Inc. (“GeneOne” KOSPI: 011000) is an international DNA vaccine and product developer, and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines and products to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. For more information, visit

Materials in this press release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. These statements can be identified by the fact that they do not relate strictly to historical or current facts. They include words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be incorrect. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of GeneOne stock. It is also important to read the disclosure notice contained in many of the individual GeneOne documents available on the website, as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christy Franco
Like >
VGXI, Inc. - cGMP Plasmid DNA Manufacturing

Visit website


VGXI Logo - Quality... It's in our DNA